The role of GIP signaling in glucose-mediated AgRP neuron inhibition (Figure 1) is consistent with the anorexigenic effects and obesity treatment efficacy of GIPR agonists. This evidence concerns the gene AGRP and obesity due to melanocortin 4 receptor deficiency.